Table_1_Overcoming Limitations of Cisplatin Therapy by Additional Treatment With the HSP90

A research document describing an in vitro study investigating the HSP90 inhibitor onalespib as a combination therapy to overcome cisplatin resistance. The document, authored by Anja Charlotte Lundgren Mortensen and last updated in May 2026, details methods assessing cell viability, proliferation, migration, apoptosis, and DNA damage response in ovarian and head and neck cancer cell models. Results indicate onalespib enhances cisplatin efficacy in a dose-dependent manner.

Use Cases

• Analyzing the molecular mechanisms of cisplatin resistance reversal based on the described assessment of HSP90 client protein downregulation.
• Evaluating combination therapy efficacy for cancer treatment based on in vitro results showing reduced cell viability and migration.
• Studying DNA damage response and repair delays in cancer cells based on the reported increase in double-strand breaks from combination treatment.
• Investigating apoptotic signaling pathways potentiated by drug combinations based on the described increase in apoptotic activity.

Strengths

• The document provides a detailed methodological description including cell viability assays, western blotting, and apoptosis evaluation.
• Results are specific, noting dose-dependent efficacy enhancement and the most persistent DNA damage occurring in the combination therapy group.
• The dataset is openly licensed under CC-BY-4.0, permitting reuse with attribution.

Limitations

• The dataset is a 13.5 KB DOCX file containing textual research description; no structured, machine-readable data (e.g., numerical results tables) is provided.
• Row count and column-level documentation are absent, limiting direct analysis of the underlying experimental data.
• The data is limited to in vitro cell line models; its direct applicability to in vivo or clinical contexts is not established.

Provenance

Source

figshare

Collection Method

In vitro laboratory study on cancer cell models.

Freshness

Last updated 2026-05-12 15:05:50.